NYSEAMERICAN:CVM Cel-Sci Q4 2025 Earnings Report $1.66 +0.17 (+11.41%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$1.65 -0.01 (-0.54%) As of 09/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings History Cel-Sci EPS ResultsActual EPS-$0.76Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACel-Sci Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACel-Sci Announcement DetailsQuarterQ4 2025Date12/23/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Cel-Sci Earnings HeadlinesCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | finance.yahoo.comCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | businesswire.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 20 at 1:00 AM | Paradigm Press (Ad)CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory ...August 4, 2026 | finance.yahoo.comCEL-SCI Corporate Event Calendar | AMEX:CVMJuly 16, 2026 | benzinga.comCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerJuly 13, 2026 | finance.yahoo.comSee More Cel-Sci Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cel-Sci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cel-Sci and other key companies, straight to your email. Email Address About Cel-SciCel-Sci (NYSEAMERICAN:CVM) is a biotechnology company focused on developing investigational immunotherapies for cancer and infectious diseases. The company’s lead product candidate is Multikine (leukocyte interleukin injection), an immunotherapy designed to stimulate the immune system against cancer. Multikine has primarily been studied as a potential treatment for patients with newly diagnosed, locally advanced primary head and neck cancer before standard surgery, radiation, or chemotherapy. Cel-Sci also develops therapies using its LEAPS (Ligand Epitope Antigen Presentation System) technology platform. The platform is designed to direct and regulate immune responses and has been investigated for potential applications in infectious diseases, autoimmune disorders, and cancer. These products remain investigational and are subject to clinical and regulatory evaluation. Founded in 1983, Cel-Sci is headquartered in Vienna, Virginia. The company has conducted clinical development activities in the United States and internationally. Geert Kersten serves as the company’s chief executive officer and has been involved in leading Cel-Sci’s development programs.View Cel-Sci ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
